{"disease":{"id":"androgen-resistant-prostatic-cancer","name":"androgen resistant prostatic cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05551117","title":"A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":192,"lead_sponsor_name":"MacroGenics","has_results":true},{"nct_id":"NCT04381832","title":"Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT05848011","title":"A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":154,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT04844749","title":"Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":105,"lead_sponsor_name":"Veru Inc.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}